U.S. Markets open in 5 hrs 12 mins

Cytokinetics Inc (CYTK) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Cytokinetics Inc (CYTK) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics Inc has a market cap of $325.530 million; its shares were traded at around $5.95 with and P/S ratio of 14.63.

For the last quarter Cytokinetics Inc reported a revenue of $9.38 million, compared with the revenue of $-0.02 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $31.5 million, an increase of 135.6% from last year. For the last five years Cytokinetics Inc had an average revenue decline of 6.4% a year.

The reported loss per diluted share was $1.95 for the year, an increase of -24.7% from previous year. The Cytokinetics Inc had an operating margin of -282.26%, compared with the operating margin of -848.26% a year before. The 10-year historical median operating margin of Cytokinetics Inc is -293.15%. The profitability rank of the company is 2 (out of 10).

At the current stock price of $5.95, Cytokinetics Inc is traded at 31.6% premium to its historical median P/S valuation band of $4.52. The P/S ratio of the stock is 14.63, while the historical median P/S ratio is 11.13. The stock lost 29.17% during the past 12 months.

Directors and Officers Recent Trades:

  • EVP Research & Development Fady Ibraham Malik sold 1,500 shares of CYTK stock on 02/07/2019 at the average price of $7.28. The price of the stock has decreased by 18.27% since.

For the complete 20-year historical financial data of CYTK, click here.

This article first appeared on GuruFocus.